相关实验视频

Updated: May 6, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

在针对性地BikDDA向前列腺癌的输送中,PETOx-DOPE纳米脂质与563功能化

Ayca Ece Nezir¹, Zeynep Büşra Bolat^1,2,3, Ongun Mehmet Saka⁴

¹Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, İstanbul, Turkiye.

Turkish journal of biology = Turk biyoloji dergisi

|July 25, 2024

概括

这项研究引入了一种新的纳米脂质体系统,用于前列腺癌治疗中的向基因传递. 在临床前模型中,P563-PEtOx-DOPE-BikDDA配方显示出显著的瘤回归.

科学领域:

生物技术是生物技术.
纳米医学是一种纳米医学.
在瘤学瘤学.

背景情况:

前列腺癌治疗从纳米载体系统中受益,但临床适用性仍然有限.
进一步的研究对于开发有效的纳米载体策略来对抗前列腺癌至关重要.
新型纳米脂质体系统正在探索前列腺癌中向性亡基因传递的目标.

研究的目的:

开发和评估一种新的纳米脂质体系统,用于针对性地向前列腺癌传递亡基因.
在体外和体内评估P563-PEtOx-DOPE-BikDDA配方的疗效.

主要方法:

聚 (2-乙基-2-oxazoline) (PEtOx) 二氧化二氧化酸丁乙醇胺 (DOPE) 的纳米脂质体被创造出来.
纳米脂质体与前列腺特异性膜抗原 (PSMA) 向性 (P563) 结合,并装载了一种前列腺突变基因 (BikDDA).
该配方 (P563-PEtOx-DOPE-BikDDA) 在22Rv1前列腺癌细胞和CD-1裸体小鼠外移植中进行了测试.

主要成果:

该P563-PEtOx-DOPE-BikDDA配方成功地在22Rv1细胞中调节了BikDDA,诱导细胞死亡.
在体内研究表明,在用这种配方治疗的CD-1裸体小鼠异种移植中,瘤回归显著.
纳米脂质体表现出有效的向输送和治疗潜力.

结论:

P563-PEtOx-DOPE-BikDDA纳米脂质体显示出作为前列腺癌治疗的有效基因载体的希望.
这种新的纳米载体系统需要进一步研究临床转化.
向的亡基因传递是增强前列腺癌治疗的可行策略.

关键词:

在 BikDDADA 里.前列腺癌是什么意思前列腺癌是什么意思脂质体组是什么? 脂质体组是什么?563 563 是一种.聚二乙烯二氧化) 是一种聚二乙烯的化合物.有针对性的基因治疗.

更多相关视频

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...